Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Izeradjene, K.
Right arrow Articles by Houghton, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Izeradjene, K.
Right arrow Articles by Houghton, J. A.
Clinical Cancer Research Vol. 10, 6650-6660, October 1, 2004
© 2004 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Influence of Casein Kinase II in Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Human Rhabdomyosarcoma Cells

Kamel Izeradjene, Leslie Douglas, Addison Delaney and Janet A. Houghton

Division of Molecular Therapeutics, Department of Hematology-Oncology, St. Jude Children’s Research Hospital, Memphis, Tennessee

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis via the death receptors DR4 and DR5 in transformed cells in vitro and exhibits potent antitumor activity in vivo with minor side effects. Protein kinase casein kinase II (CK2) is increased in response to diverse growth stimuli and is aberrantly elevated in a variety of human cancers. Rhabdomyosarcoma tumors are the most common soft-tissue sarcoma in childhood. In this investigation, we demonstrate that CK2 is a key survival factor that protects tumor cells from TRAIL-induced apoptosis. We have demonstrated that inhibition of CK2 phosphorylation events by 5,6-dichlorobenzimidazole (DRB) resulted in dramatic sensitization of tumor cells to TRAIL-induced apoptosis. CK2 inhibition also induced rapid cleavage of caspase-8, -9, and -3, as well as the caspase substrate poly(ADP-ribose) polymerase after TRAIL treatment. Overexpression of Bcl-2 protected cells from TRAIL-induced apoptosis in the presence of the CK2 inhibitor. Death signaling by TRAIL in these cells was Fas-associated death domain and caspase dependent because dominant negative Fas-associated death domain or the cowpox interleukin 1ß-converting enzyme inhibitor protein cytokine response modifier A prevented apoptosis in the presence of DRB. Analysis of death-inducing signaling complex (DISC) formation demonstrated that inhibition of CK2 by DRB increased the level of recruitment of procaspase-8 to the DISC and enhanced caspase-8-mediated cleavage of Bid, thereby increasing the release of the proapoptotic factors cytochrome c, HtrA2/Omi, Smac/DIABLO, and apoptosis inducing factor (AIF) from the mitochondria, with subsequent degradation of X-linked inhibitor of apoptosis protein (XIAP). To further interfere with CK2 function, JR1 and Rh30 cells were transfected with either short hairpin RNA targeted to CK2{alpha} or kinase-inactive CK2{alpha} (K68M) or CK2{alpha}' (K69M). Data show that the CK2 kinase activity was abrogated and that TRAIL sensitivity in both cell lines was increased. Silencing of CK2{alpha} expression with short hairpin RNA was also associated with degradation of XIAP. These findings suggest that CK2 regulates TRAIL signaling in rhabdomyosarcoma by modulating TRAIL-induced DISC formation and XIAP expression.




This article has been cited by other articles:


Home page
Mol. Cell. ProteomicsHome page
J. S. Duncan, L. Gyenis, J. Lenehan, M. Bretner, L. M. Graves, T. A. Haystead, and D. W. Litchfield
An Unbiased Evaluation of CK2 Inhibitors by Chemoproteomics: Characterization of Inhibitor Effects on CK2 and Identification of Novel Inhibitor Targets
Mol. Cell. Proteomics, June 1, 2008; 7(6): 1077 - 1088.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
F. A. Piazza, M. Ruzzene, C. Gurrieri, B. Montini, L. Bonanni, G. Chioetto, G. Di Maira, F. Barbon, A. Cabrelle, R. Zambello, et al.
Multiple myeloma cell survival relies on high activity of protein kinase CK2
Blood, September 1, 2006; 108(5): 1698 - 1707.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G. Wang, K. A. Ahmad, and K. Ahmed
Role of Protein Kinase CK2 in the Regulation of Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Apoptosis in Prostate Cancer Cells
Cancer Res., February 15, 2006; 66(4): 2242 - 2249.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Izeradjene, L. Douglas, D. M. Tillman, A. B. Delaney, and J. A. Houghton
Reactive Oxygen Species Regulate Caspase Activation in Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Resistant Human Colon Carcinoma Cell Lines
Cancer Res., August 15, 2005; 65(16): 7436 - 7445.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Izeradjene, L. Douglas, A. Delaney, and J. A. Houghton
Acknowledgment and Apology: Text Copied from Biochemical Journal
Clin. Cancer Res., July 15, 2005; 11(14): 5329 - 5329.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Yamane and T. J. Kinsella
Casein Kinase 2 Regulates Both Apoptosis and the Cell Cycle Following DNA Damage Induced by 6-Thioguanine
Clin. Cancer Res., March 15, 2005; 11(6): 2355 - 2363.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.